Treatment Information

Back

Brain – Glioblastoma Multiforme treatment details. Immunotherapy.

Osaka University Graduate School of Medicine, Osaka, Japan.

Survival: monthsCountry:Japan
Toxiciy Grade:2City/State/Province:Osaka
Treatments:ImmunotherapyHospital:Osaka University Graduate School of Medicine
Drugs:Journal:Link
Date:May 2008

Description:

Patients:  This phase II study involved 21 patients (7 women and 14 men) with recurrent glioblastoma multiforme.  They ranged in age from 20 to 76 years old.
 
Treatment:  Patients were given a vaccine (immunological therapy) designed to make their immune system destroy tumor cells. 

Toxicities:  There were not any grade 3 or 4 toxicities.  All patients had a local inflammatory response with erythema at the site where the vaccine was injected. 

Results:  The median overall survival after the initial vaccination was 36.7 weeks.  The median overall survival after tumor recurrence in the vaccinated patients was 46 weeks. 

Correspondence:  Dr. Shuichi Izumoto



Back